HUE051875T2 - Egyláncú oligonukleotidok bõrrendellenességek orvosi kezelésében történõ alkalmazásra - Google Patents

Egyláncú oligonukleotidok bõrrendellenességek orvosi kezelésében történõ alkalmazásra

Info

Publication number
HUE051875T2
HUE051875T2 HUE16734570A HUE16734570A HUE051875T2 HU E051875 T2 HUE051875 T2 HU E051875T2 HU E16734570 A HUE16734570 A HU E16734570A HU E16734570 A HUE16734570 A HU E16734570A HU E051875 T2 HUE051875 T2 HU E051875T2
Authority
HU
Hungary
Prior art keywords
medical treatment
skin disorders
stranded oligonucleotides
oligonucleotides
stranded
Prior art date
Application number
HUE16734570A
Other languages
English (en)
Inventor
Holmgren Spetz
Peter Järver
Annette Skoeld
Original Assignee
Tirmed Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tirmed Pharma Ab filed Critical Tirmed Pharma Ab
Publication of HUE051875T2 publication Critical patent/HUE051875T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
HUE16734570A 2015-06-15 2016-06-14 Egyláncú oligonukleotidok bõrrendellenességek orvosi kezelésében történõ alkalmazásra HUE051875T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1550814 2015-06-15

Publications (1)

Publication Number Publication Date
HUE051875T2 true HUE051875T2 (hu) 2021-04-28

Family

ID=56345083

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16734570A HUE051875T2 (hu) 2015-06-15 2016-06-14 Egyláncú oligonukleotidok bõrrendellenességek orvosi kezelésében történõ alkalmazásra

Country Status (15)

Country Link
US (1) US10626401B2 (hu)
EP (1) EP3307277B1 (hu)
AU (1) AU2016280663B2 (hu)
CA (1) CA2989371C (hu)
CY (1) CY1123639T1 (hu)
DK (1) DK3307277T3 (hu)
ES (1) ES2834906T3 (hu)
HR (1) HRP20202066T1 (hu)
HU (1) HUE051875T2 (hu)
LT (1) LT3307277T (hu)
PL (1) PL3307277T3 (hu)
PT (1) PT3307277T (hu)
RS (1) RS61274B1 (hu)
SI (1) SI3307277T1 (hu)
WO (1) WO2016202779A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504124D0 (en) 2015-03-11 2015-04-22 Proqr Therapeutics B V Oligonucleotides
JP6871175B2 (ja) 2015-05-21 2021-05-12 ウィングス セラピューティクス,インコーポレイテッド ジストロフィー型表皮水疱症を処置するためのアンチセンスオリゴヌクレオチド
GB201714330D0 (en) * 2017-09-06 2017-10-18 Järver Peter Oligonucleotides
WO2019199720A1 (en) * 2018-04-09 2019-10-17 The Trustees Of Princeton University Compositions comprising immune system activators and method of using same
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8101345B1 (en) * 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
WO2008147956A2 (en) 2007-05-25 2008-12-04 Centocor, Inc. Toll-like receptor 3 modulators and uses thereof
US20100040576A1 (en) 2007-12-18 2010-02-18 The Texas A&M University System Modified Oligonucleotides For The Treatment Of Hepatitis C Infection

Also Published As

Publication number Publication date
US10626401B2 (en) 2020-04-21
EP3307277A1 (en) 2018-04-18
PT3307277T (pt) 2020-12-30
CA2989371A1 (en) 2016-12-22
AU2016280663A1 (en) 2018-01-18
CA2989371C (en) 2024-02-06
LT3307277T (lt) 2020-12-28
EP3307277B1 (en) 2020-10-07
US20180142246A1 (en) 2018-05-24
ES2834906T3 (es) 2021-06-21
AU2016280663B2 (en) 2021-04-29
WO2016202779A1 (en) 2016-12-22
SI3307277T1 (sl) 2021-02-26
PL3307277T3 (pl) 2021-03-08
HRP20202066T1 (hr) 2021-04-30
RS61274B1 (sr) 2021-01-29
DK3307277T3 (da) 2020-12-07
CY1123639T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
IL284423B (en) Antisense oligonucleotides for the treatment of Pompe disease
HK1251257A1 (zh) 用於醫治疾病的外泌體的用途
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
HK1257321A1 (zh) 用於治療腦組織的組織摧毀術治療系統和方法
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
RS61274B1 (sr) Jednolančani oligonukleotidi za upotrebu u medicinskom lečenju poremećaja kože
PT3180434T (pt) Chamarizes oligonucleotídicos para o tratamento da dor
IL246855A0 (en) Materials for use in the treatment of retinitis
IL277238A (en) Modified oligonucleotides for use in the treatment of tauopathy
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
ZA201807692B (en) New use of product for skin treatment
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合
IL259381B (en) Miravegron for the treatment of retinal diseases
GB201604359D0 (en) Treatment of tissue disorders
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
IL274132A (en) Treatment of skin problems
PL3352777T3 (pl) Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona
GB201501588D0 (en) Novel polymorph for use in treatment of inflammatory, skin and pruritic disorders
GB201308302D0 (en) Cream for treatment of the skin